Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1067-1077

  Shay, Jessica E S ^a,b   Imtiyaz, Hongxia Z ^a,c   Sivanand, Sharanya ^a,b   Durham, Amy C ^d   Skuli, Nicolas ^a,c,e   Hsu, Sarah ^a,b   Mucaj, Vera ^a,b   Eisinger Mathason, T S Karin ^a,b   Krock, Bryan L ^a,b   Giannoukos, Dionysios N ^c   Celeste Simon, M ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CANCER SIZE; CELL INFILTRATION; COLITIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ACRIFLAVINE; ANIMALS; ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MACROPHAGES; MICE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901997518     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu004     Document Type: Article

References (59)

1. Virchow, R. (1863) Aetologie der neoplastichen Geshwulste. Pathogenie der neoplastischen Geschwustle. Die Krankhafter Geschwulste, 1, 57-101.
2. Danese, S. et al. (2010) Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene, 29, 3313-3323.
3. Vakkila, J. et al. (2004) Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol., 4, 641-648.
4. Balkwill, F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
5. Rhodes, J.M. et al. (2002) Inflammation and colorectal cancer: IBDassociated and sporadic cancer compared. Trends Mol. Med., 8, 10-16.
6. Eaden, J.A. et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48, 526-535.
7. O'Connor, P.M. et al. (2010) Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm. Bowel Dis., 16, 1411-1420.
8. Bertout, J.A. et al. (2008) The impact of O2 availability on human cancer. Nat. Rev. Cancer, 8, 967-975.
9. Ruan, K. et al. (2009) Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem., 107, 1053-1062.
10. Murdoch, C. et al. (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood, 104, 2224-2234.
11. Saleh, M. et al. (2011) Innate immune mechanisms of colitis and colitisassociated colorectal cancer. Nat. Rev. Immunol., 11, 9-20.
12. Solinas, G. et al. (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol., 86, 1065-1073.
13. Tanner, A.R. et al. (1984) Macrophage activation, chronic inflammation and gastrointestinal disease. Gut, 25, 760-783.
14. Fang, H.Y. et al. (2009) Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood, 114, 844-859.
15. Crowther, M. et al. (2001) Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol., 70, 478-490.
16. Waldner, M.J. et al. (2010) The molecular therapy of colorectal cancer. Mol. Aspects Med., 31, 171-178.
17. Bingle, L. et al. (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol., 196, 254-265.
18. Semenza, G.L. (2007) Life with oxygen. Science, 318, 62-64.
19. Majmundar, A.J. et al. (2010) Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell, 40, 294-309.
20. Cockman, M.E. et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 275, 25733-25741.
21. Jaakkola, P. et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292, 468-472.
22. Imtiyaz, H.Z. et al. (2010) Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest., 120, 2699-2714.
23. Talks, K.L. et al. (2000) The expression and distribution of the hypoxiainducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157, 411-421.
24. White, J.R. et al. (2004) Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics, 83, 1-8.
25. Semenza, G.L. (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 12, 853-859.
26. Keith, B. et al. (2012) HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer, 12, 9-22.
27. Keith, B. et al. (2007) Hypoxia-inducible factors, stem cells, and cancer. Cell, 129, 465-472.
28. Wiesener, M.S. et al. (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J., 17, 271-273.
29. Mucaj, V. et al. (2012) Effects of hypoxia and HIFs on cancer metabolism. Int. J. Hematol., 95, 464-470.
30. Burke, B. et al. (2003) Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol., 163, 1233-1243.
31. Burke, B. et al. (2002) Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol., 196, 204-212.
32. Lewis, J.S. et al. (1999) Macrophage responses to hypoxia: relevance to disease mechanisms. J. Leukoc. Biol., 66, 889-900.
33. Murdoch, C. et al. (2005) Macrophage migration and gene expression in response to tumor hypoxia. Int. J. Cancer, 117, 701-708.
34. Takeda, N. et al. (2010) Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev., 24, 491-501.
35. Cramer, T. et al. (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell, 112, 645-657.
36. Shay, J.E. et al. (2012) Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Semin. Cell Dev. Biol., 23, 389-394.
37. Semenza, G.L. (2006) Development of novel therapeutic strategies that target HIF-1. Expert Opin. Ther. Targets, 10, 267-280.
38. Semenza, G.L. (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci., 33, 207-214.
39. Semenza, G.L. (2012) Hypoxia-inducible factors in physiology and medicine. Cell, 148, 399-408.
40. Lee, K. et al. (2009) Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA, 106, 17910-17915.
41. Wong, C.C. et al. (2012) Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. (Berl)., 90, 803-815.
42. Wainwright, M. (2001) Acridine-a neglected antibacterial chromophore. J. Antimicrob. Chemother., 47, 1-13.
43. Stadtfeld, M. et al. (2005) Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development, 132, 203-213.
44. Tomita, S. et al. (2000) Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha. Mol. Endocrinol., 14, 1674-1681.
45. Pan, Y. et al. (2004) p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene, 23, 4975-4983.
46. Okayasu, I. et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 98, 694-702.
47. Okayasu, I. et al. (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut, 39, 87-92.
48. Okayasu, I. et al. (2002) Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J. Gastroenterol. Hepatol., 17, 1078-1083.
49. Hogan, S.P. et al. (2006) Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J. Allergy Clin. Immunol., 118, 257-268.
50. Hooper, L.V. et al. (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol., 4, 269-273.
51. Hans, W. et al. (2000) The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur. J. Gastroenterol. Hepatol., 12, 267-273.
52. Ullman, T.A. et al. (2011) Intestinal inflammation and cancer. Gastroenterology, 140, 1807-1816.
53. Barnes, P.J. et al. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med., 336, 1066-1071.
54. Pahl, H.L. (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18, 6853-6866.
55. Dirkx, A.E. et al. (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol., 80, 1183-1196.
56. Murdoch, C. et al. (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer, 8, 618-631.
57. Onnis, B. et al. (2009) Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med., 13, 2780-2786.
58. Hassan, S. et al. (2011) Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci., 102, 2206-2213.
59. Lim, M.J. et al. (2012) Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis. Int. J. Biochem. Cell Biol., 44, 1214-1222.